Neuroendocrine Tumors - Epidemiology Forecast to 2030

NETs are cancers that begin in the cells that release hormones into the bloodstream. NETs can occur anywhere in the body. Most develop slowly and may not cause symptoms in the early stages. The symptoms associated with NETs vary depending on where in the body they originate. Gastrointestinal (GI) NETs may cause diarrhea, constipation, or stomach pains, and lung NETs may cause wheezing or a persistent cough. Other symptoms include flushing, cramps, low blood sugar, or heart problems. The exact cause of NETs is not known, but they develop when neuroendocrine cells develop mutations in the DNA.

To forecast the diagnosed incident cases of NETs, and five-year diagnosed prevalent cases of NETs in the 8MM, the publisher epidemiologists conducted a thorough literature review to find country-specific sources that provided data for the above-mentioned segmentations of the general population in the 8MM. In order to improve the accuracy of the forecast the publisher epidemiologists used studies that provided data based on uniform diagnostic codes and disease definition for these parameters across the 8MM.

In the 8MM, the publisher epidemiologists forecast that the diagnosed incident cases of NETs will increase from 107,776 cases in 2020 to 133,312 cases in 2030, at an Annual Growth Rate (AGR) of 2.37%. Urban China will have the highest number of NET cases among the 8MM throughout the forecast period, while Spain will have the lowest. In the 8MM, the publisher epidemiologists forecast that the five-year diagnosed prevalent cases of NETs will increase from 372,035 cases in 2020 to 465,410 cases in 2030, at an AGR of 2.51%.

Scope

• The Neuroendocrine Tumors (NET) Epidemiology Report and Epidemiology provides an overview of the risk factors and global trends of NETs in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of NETs, based on country-specific studies published in peer-reviewed journals. The diagnosed incident cases of NETs are further segmented by sex, age, type, stage at diagnosis, grade and differentiation. The publisher epidemiologists also provide diagnosed incident cases of paraganglioma and pheochromocytoma. The forecast also includes five-year diagnosed prevalent cases of NETs in the 8MM for the forecast period.
• The neuroendocrine tumors epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The Neuroendocrine Tumors Epidemiology Report will allow you to:

• Develop business strategies by understanding the trends shaping and driving the global hyperparathyroidism market.
• Quantify patient populations in the global neuroendocrine tumors market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups, sex and type of NET that present the best opportunities for therapeutics in each of the markets covered.
• Understand the population of paraganglioma and pheochromocytoma cases.